Drug Approval | April 29, 2025
Closure of USFDA inspection at Zydus' API Unit at Dabhasa, Gujarat
The inspection concluded with 6 observations and none of them were related to Data Integrity
The inspection concluded with 6 observations and none of them were related to Data Integrity
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Subscribe To Our Newsletter & Stay Updated
